Den europeiske union -
norsk -
EMA (European Medicines Agency)
clopidogrel acino
acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.
Norge -
norsk -
Statens legemiddelverk
equasym depot 20 mg
takeda pharmaceuticals international ag ireland branch - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 20 mg
Norge -
norsk -
Statens legemiddelverk
equasym depot 10 mg
takeda pharmaceuticals international ag ireland branch - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 10 mg
Norge -
norsk -
Statens legemiddelverk
equasym depot 30 mg
takeda pharmaceuticals international ag ireland branch - metylfenidathydroklorid - kapsel med modifisert frisetting, hard - 30 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 50 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 50 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 30 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 30 mg
Norge -
norsk -
Statens legemiddelverk
aduvanz 70 mg
takeda pharmaceuticals international ag ireland branch - lisdeksamfetamindimesilat - kapsel, hard - 70 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
verquvo
bayer ag - vericiguat - hjertefeil - hjertetapi - treatment of symptomatic chronic heart failure.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
eylea
bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - Øyemidler - eylea er indikert for voksne for behandling av:neovascular (våt) aldersrelatert makuladegenerasjon (amd);synshemming på grunn av flekker ødemer sekundært til retinal vene okklusjon (gren rvo eller sentrale rvo);synshemming på grunn diabetiker macular ødemer (dme);synshemming på grunn av begrenset choroidal neovascularisation (nærsynt cnv).